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identification of a specific elemental formula for an
unknown compound which includes but is not limited to a
metabolite. The method includes calculating a natural abundance probability (NAP) of a given isotopologue for isotopes of non-labelling elements of an unknown compound.
Molecular fragments for a subset of isotopes identified using
the NAP are created and sorted into a requisite cache data
structure to be subsequently searched. Peaks from raw
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Fourier transform mass spectra are separated. A set of
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and combining with additional isotopes and then statistically
filtering the results based on NAP and mass-to-charge (m/2)
matching probabilities. An unknown compound is identified
and its corresponding elemental molecular formula (EMF)
from statistically-significant caches of isotopologues with
compatible IMFs.
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METHOD AND SYSTEM FOR
IDENTIFICATION OF METABOLITES USING
MASS SPECTRA

abundance probability (NAP) of a given isotopologue for the
set of isotopes it contains or a relative NAP if the labeling
isotopes are present; ii) algorithms to efficiently build and
sort large (multiterabyte) caches of molecular fragments for
a subset of isotopes being searched; iii) algorithms that
characterize peaks from a raw spectrum and separate
sample-specific peaks from various spectral artefacts seen in
ultra-high resolution Fourier transform mass spectra; iv)
algorithms that create sets of possible IMFs by iteratively
searching the molecular fragment caches and combining
with additional isotopes and then statistically filtering the
results based on NAP and mass-to-charge (m/z) matching
probabilities; and v) an algorithm that identify a metabolite
and its corresponding EMF from statistically-significant
cliques of isotopologues with compatible IMFs. FIG. lA
(flowchart) and FIG. 1B (system schematic) show an overview of how these five components are used to determine
statistically significant EMF cliques.
Again, all five components are necessary to determine
IMFs of specific isotopologues and related offset peaks via
the identification of their associate EMF clique representing
a specific metabolite or a set of metabolites that are structural isomers. Also, this approach is applicable to a directed
search of known EMFs by building an isotopically-resolved
cache (Component 2) for only these known EMFs. And this
approach is applicable to the analysis of tandem mass
spectroscopic (MSn) data, where the set of possible IMFs of
specific fragment isotopologues are probabilistically intersected with the set of possible IMFs of the parent isotopologue.
Component 1.

CROSS REFERENCE TO RELATED
APPLICATION
This application claims benefit of U.S. Provisional Application No. 62/358,411, filed Jul. 5, 2016, which is hereby
incorporated by reference.

5
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FIELD OF THE INVENTION
The presently-disclosed subject matter relates to methods
and systems for identification of an unknown compound. In
particular, the presently-disclosed subject matter relates to
identification of an unknown compound, which includes but
is not limited to metabolites, detected by mass spectrometry,
including ultra-high resolution mass spectrometry. The presently-disclosed subject matter further relates to identification of molecular formulas of detected compounds including
metabolites.

15

20

BACKGROUND OF THE INVENTION
25

Metabolomics is a systematic detection and study of the
metabolites (small biomolecules <2000 Dalton) present in
samples derived from living systems. Recent advances in
ultra-high resolution mass spectrometry enables rapid detection of tens of thousands of isotopologues (i.e. mass equivalent sets of isotopomers) representing thousands of metabolites. Yet, the necessity for metabolite identification,
quantitative analysis, and interpretation, within the context
of relevant metabolic networks, represents key barriers to
the use of this avalanche of information-rich, phenotypic
metabolomics data. In fact, over 50% of detected metabolites remain unidentified in ultra-high resolution mass spectra and there is low confidence in those metabolites identified without a comparison to standards. With stable isotoperesolved metabolomics (SIRM) experiments, comparison to
millions (or billions) of isotopically-different chemical standards is not possible.

30

35

PEJ

j=l

40

SUMMARY OF THE INVENTION
45

This disclosure describes the development, prototyping,
and implementation of a novel algorithm that detects
metabolites at a desired statistical confidence and determines
their specific elemental molecular formula (EMF) using
detected sets (i.e. cliques) of related isotopologue peaks with
compatible isotope-resolved molecular formulae (IMFs ).
The methodology works on both mass spectra derived from
non-SIRM experiments, but especially on mass spectra from
SIRM experiments that contain metabolites labeled with
specific stable isotopes like 13 C, 15 N, and 2 H from a given
labeling source and/or from natural abundance. This
approach has none of the limitations of current methods that
can only detect known metabolites in a database. Thus this
new method enables the full interpretation of untargeted
metabolomics studies through the identification of metabolites at the level of structural isomers representing the same
EMF.
The approach outlined in this disclosure requires five key
components to overcome the inherent IMF combinatorial
search problem and then identify statistically significant
EMFs from tens of thousands of possible IMFs. The five key
components are: i) algorithms that calculate the natural

n
n

NAP=

50

55

60

65

The above equations describe the calculation of the natural abundance probability (NAP) for specific isotopicallyresolved molecular formulas. In the case where a specific
isotope(s) comes from a labeling source, a relative NAP is
calculated where that isotope's contribution to the element's
probability (PE) is omitted. For isotope combinations for an
element containing 3 or more isotopes, one of which is
labeled, a relative NAP can be calculated using the remaining isotopes else the relative NAP is set to one.
Component 2.
The problem of searching for probable isotopically-resolved molecular formulas is a huge combinatorial problem
that becomes intractable on even large supercomputers for
molecular masses over 500 Daltons. In order to make this
problem tractable, you must build a large multiterabyte
sorted cache of plausible molecular formula fragments using
the NAP from Component 1 and metabolite bonding pattern
rules for the elements in the cache. In addition, efficient
merge sort algorithms are required to effectively sort a list
containing 100's of billions of elements and keep the needed
disk space required to build the cache to roughly twice the
size of the final sorted cache. The cache reduces the molecular formula search time by a ratio of the time to build the
cache (typically> 1,000 CPU hours) versus the time it takes
to search the cache (i.e. milliseconds or better). An example
metabolite bonding pattern rule is the number of hydrogen
atoms in a molecular formula is bounded by the number of

US 10,607,723 B2
3
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available valence electrons. Current prototype caches take
roughly 3 terabytes of storage; however, future caches
would grow with available storage capacities. Efficient utilization of the cache requires an in-memory binary search
tree approximately equal to: 16*cache_size/4096 bytes.
Component 3.
Detected peaks within spectra collected from Fourier
transform mass spectrometers have a variety of data quality
issues including m/z peak shifting (FIGS. 2A and 2B),
inconsistency in peak heights and areas (FIG. 3), and the
presence of artefactual peaks. These data quality issues arise
from: i) limitations in digital resolution (FIG. 4); ii) problems with scan-level consistency (FIG. 5); iii) Fourier transform-based artefacts (FIG. 6), and iv) the presence of
contaminants. However, standard peak picking methods that
average across scans create huge data quality issues. Therefore, an integrated procedure using a combination of new
scan-level peak characterization methods along with artefact
peak detection methods are required to derive high quality
peak characteristics associated with specific isotopologues.
Peak characterization at the scan-level is implemented by
removing noise peaks per scan, corresponding peaks across
scans, and performing normalization of peak heights/areas
across scans. The resulting correspondence peaks are used to
derive high quality peak heights and areas (FIGS. 7 and 8)
while removing many of the high peak density artefacts
present but inconsistent at the scan-level. Separate high peak
density analyses and contaminant detection will remove or
mark the remaining artefactual peaks. A list of contaminant
molecules can be based on expected contaminate molecules
from the plastics and solvents used in sample preparation
including polymers like polyethylene glycol (PEG) and
polymer detergents like triton X-100 or derived from quality
control samples directly. A difference matrix generated from
this list of expected molecules is compared to the difference
matrix generated from the peak list derived from a mass
spectrum. Rows between the two matrices with a statistically significant number of differences that match are used
to assign expected contaminant peaks and derive offsets
present in the spectrum.
Component 4.
Each isotopologue is identified by a peak with a specific
mass to charge ratio (m/z ratio) position in the ID mass
spectrum. The peak also has an intensity related to the
number of ions physically detected in the mass spectrometer.
For each characterized isotopologue peak, a set of possible
isotopically-resolved molecular formulas (IMFs) are calculated within a specified accuracy tolerance using Component
2 to build specific isotopically-resolved molecular formulas
that are then filtered against: i) the NAP from Component 1;
ii) a statistical measure of how well the molecular formula
matches the m/z ratio (m/z matching probability); and iii)
metabolite bonding pattern rules.
Component 5.
A clique of compatible isotopologue peaks associated
with a specific EMF is identified via a nonempty intersection
between their sets of possible EMFs identify from their
possible IMFs. In addition, each complementary pair of
isotopologues (i.e. has equal numbers of labeling isotopes)
from a specific EMF clique is statistically evaluated using
both m/z matching probabilities from Component 3 and a
log ratio of isotopologue intensities statistically compared to
the log ratio of each IMF NAP from Component 1 (log-ratio
match probability). The isotopologue intensities used in the
ratios are derived from associated characterized peaks. Each
complementary pair represents a statistically evaluated piece
of evidence supporting the existence of the associate EMF

clique in the mass spectrum. Specific EMF cliques are
identified by statistically evaluating the sum of complementary pair probabilities/likelihoods. Restated, a goodness-offit score for a clique is created from the sum of pair
probabilities/likelihoods. Statistically significant goodnessof-fit scores are evaluated against randomly generated
cliques derived from isotopologues of incompatible cliques
at a certain significance level. The resulting analysis identifies EMF cliques of isotopologue peaks associated with
one or more structural isomers at a specified level of
statistical significance.
Table 1 (below) shows a proof of concept application of
implementation of Components 1-5 to a peak list derived
from a Thermo Orbitrap Fusion Tribrid FTMS spectrum of
a biological sample that had been treated with the ECF
(2Cl-CO 2 Et) chemoselection agent. Twenty-seven out of
the 31 verified EMF cliques were detected and assigned by
the prototype tool, representing an 87% correctly assigned
rate. Peaks from one clique were misassigned, representing
a 3.6% false discovery rate (FDR). FIGS. 8, 9A and 9B
demonstrate the quality of the fit between observed and
theoretical relative isotopologue intensities for a detected
EMF clique and across a targeted set of verified cliques. The
peak characterization in Component 3has greatly reduced
known FTMS ion suppression effects as illustrated by the
slope between normalized NAP values and relative intensities in FIG. 9A. These results clearly show the utility of this
approach to derive validated EMFs from FTMS peak lists.
The current prototype is able to efficiently search a roughly
4.8 quintillion (4.8xl0 18 ) IMF space for each peak's m/z,
based on molecular masses <=2000 daltons, but larger IMF
spaces are searchable.
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Validated EMFs from Biological Sample Detected Using
a Prototype Implementation
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EMF

Assignment

Cl0ElHl 7N1Na1O4
Cl0ElHl 7N1Na1O6
C10E1H18N2Na1O5
C10E1H19N1Na1O4
C11E1H19N1Na1O6
C11E1H21N1Na1O4
C11E1H21N3Na1O5
C11E1H23N4O4
C12E1Hl 7N3Na1O6
C12E1H20N3O4
C12E1H21N1Na1O6
C12E1H22N2Na1O6
C13E1H23N1Na1O6
C14E1H19N1Na1O4
C14E1H21N3Na1O6
C14E1H22N3O6
C15E1H25N4O5
C16E1H20N2Na1O4
Cl 7E1H30N2Na1O8Sl
C7E1H13N1Na104
C8E1H15N1Na104
C8E1H15N1Na105
C9E1H15N1Na106
C9E1Hl 7N1Nal 04
C9E1Hl 7N1Nal 05
C10E1H19N1Na1O4Sl
C 18E1H29N407

Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Assigned
Alternative
Assignment
Not Assigned
Not Assigned
Not Assigned
Not Assigned

C14E1H24N2Na1O8S2
C14E1H26N2Na1O6
C15E1H26N2Na1O8Sl
C16E1H28N2Na1O8S2

Clique Size
4
3
4
4
5
5
5
2
2
5
3
2
4
5
3
3
2
6
8
3
5
3
3
5
3
4
2
NIA
NIA
NIA
NIA
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Furthermore, this methodology can be extended to sets of
detected EMF cliques (super-cliques) representing different
chemical derivitizations of a specific metabolite. Differences
in the EMFs reflect additions of known chemoselective tags
and/or adducts to specific metabolites represented by the
EMF of the base clique. A goodness-of-fit score can be
calculated for super-cliques of known derivitizations. Furthermore, a comparison of the matrix of log intensity ratios
for specific cliques can be used to identify super-cliques of
unknown derivitizations.
The present invention, in one form thereof is directed to
a method for mass spectrometry data analysis for identification of a specific elemental molecular formula (EMF) for
an unknown compound. The method includes calculating a
natural abundance probability (NAP) of a given isotopologue for isotopes of non-labeling elements of an unknown
compound and creating and sorting caches of molecular
fragments for a subset of isotopes identified using the NAP,
into a requisite cache data structure, to be searched. Peaks
from raw spectrum from mass spectrometry for an unknown
compound are characterized and sample-specific peaks are
separated from various spectral artefacts seen in ultra-high
resolution Fourier transform mass spectra. Sets of possible
isotope-resolved molecular formulae (IMFs) are created by
iteratively searching the molecular fragment caches and
combining with additional isotopes and then statistically
filtering the results based on NAP and mass-to-charge (m/z)
matching probabilities. An unknown compound is identified
and its corresponding EMF determined from statisticallysignificant cliques of isotopologues with compatible IMFs.
The present invention is another form thereof is directed
to a system of mass spectrometry data analysis for identification of a specific elemental molecular formula (EMF) for
an unknown compound. The system includes computer
memory adapted to store mass spectrometry data for an
unknown compound and a computer processor adapted for
performing analytics on mass spectrometry data from mass
spectrometry for the unknown compound. The processor
calculates a natural abundance probability (NAP) of a given
isotopologue for isotopes of non-labeling elements of an
unknown compound. Further, the processor creates and sorts
caches of molecular fragments for a subset of isotopes
identified using the NAP, into a requisite cache data structure, to be searched. Next, peaks from raw spectrum are
characterized and sample-specific peaks are separated from
various spectral artefacts and noise seen in ultra-high resolution Fourier transform mass spectra. Further, the processor
creates sets of possible isotope-resolved molecular formulae
(IMF) by iteratively searching the molecular fragment
caches and combining with additional isotopes and then
statistically filtering the results based on NAP and mass-tocharge (m/z) matching probabilities. Finally, the processor
identifies an unknown compound and its corresponding
EMF from statistically-significant cliques of isotopologues
with compatible IMFs.

FIG. lA is a flowchart showing a metabolite identification
process using ultra-high resolution mass spectrometry in
accordance with the present invention.
FIG. lB is a schematic showing how five components of
the identification process interact with one another to identify an unknown compound in accordance with the present
invention.
FIG. lC is a schematic of a system for metabolite identification in accordance with the present invention.
FIGS. 2A and 2B are two respective graphs showing
spectra collected from Founer transform mass spectrometers
showing peak m/z offset patterns detected, where FIG. 2A
shows Thermo Orbitrap Fusion Tribrid FTMS spectrum
mainly due to digital resolution and scan-level consistency
issues and FIG. 2B shows Bruker SolariX XR ICR FTMS
spectrum mainly due to ringing artefacts derived from
truncation issues in the Fourier transformation.
FIG. 3 includes graphs showing Relative Standard Deviation of peak heights and areas across raw scans in a Thermo
Orbitrap Fusion Tribrid FTMS spectrum.
FIGS. 4A-4C are graphs demonstrating limitations in
digital resolution and scan-level inconsistencies leading to
peak m/z offsets in a Thermo Orbitrap Fusion Tribrid FTMS
spectrum in which FIG. 4A shows average spectrum for a
peak across all transients, FIG. 4B is a set of 11 transient
scans, and FIG. 4C shows highest intensity point for each
scan.
FIG. 5 shows scan-level inconsistencies in signal and
noise for a Thermo Orbitrap Fusion Tribrid FTMS spectrum.
FIGS. 6A-C show three types of high peak density
FTMS-based spectral artefacts: FIG. 6A fuzzy sites, FIG. 6B
ringing, and FIG. 6C partial ringing.
FIG. 7 illustrates the improved relative Standard Deviation of peak heights and areas across normalized scans in a
Thermo Orbitrap Fusion Tribrid FTMS spectrum.
FIG. 8 shows a comparison of observed vs NAP theoretical relative peak heights for a clique of characterized isotopologue peaks.
FIGS. 9A and 9B show that minimal ion intensity effects
are observed after peak characterization, in which FIG. 9A
shows regression of normalized NAP versus relative intensity, and FIG. 9B is a histogram oflog NAP ratios minus log
intensity ratios.
FIG. 10 is a diagram illustrating class relationships and
modularization of parallelized natural abundance (NA) correction algorithm.
FIG. 11 is a graph showing improvement in multiprocessing NA correction running time with increasing numbers of
processors used.
FIG. 12 depicts pathways from [U- 13 C]-glucose to the
four biochemical subunits ofUDPGlcNAc. Glucose moiety
is incorporated directly. Acetyl moiety is incorporated via
glycolysis. Ribose moiety is incorporated via the pentose
phosphate pathway. Uracil moiety derives from acetyl-CoA
via the citric acid cycle to form aspartate where it is
combined with carbamoyl phosphate.
FIG. 13A lists chemical substructure model representing
the possible number of 13 C incorporation from 13 CcGlc
tracer into UDP-GlcNAc, accounting for the observed FTICR-MS isotopologue peaks.
FIG. 13B shows the structure ofUDP-GlcNAc annotated
by its chemical substructures and their biosynthetic pathways from 13 CcGlc. NAc-Glucose utilizes Gin as the nitrogen donor.
FIG. 13C is a graph showing fit of optimized chemical
substructure model parameters to F-ICR-MS isotopologue
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The novel features of the invention are set forth with
particularity in the appended claims. A better understanding
of the features and advantages of the present invention will
be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the
principles of the invention are used, and the accompanying
drawings of which:
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data of UDP-GLcNAc extracted from human cell culture
after 48 hr of growth in 13 C 6 -Glc.
FIG. 14 is a graph illustrating a deconvoluted time course
of FT-ICR-MS isotopologue peaks of UDP-GlcNAc from
human cell culture extract.

While global metabolomics, including the quantification
of a large number of metabolites in tissue or biofluids, can
identify disease states or response to therapeutics by reference to the normal condition, determining specific mechanisms, such as detecting which pathways are impacted in
particular cell types within a tissue by measuring metabolic
fluxes, requires additional information. Indeed, many
metabolites are present in different amounts in different cell
types or within compartments of cells, as well as participating in several pathways simultaneously. To identify precursor-product relationships, it is necessary to distinguish different sources of carbon, nitrogen etc. which necessitates
some means of "labeling" individual atoms so that their fate
can be traced through metabolic pathways. Traditionally this
was achieved using radioisotopes. However, stable isotopes
have several advantages, including being wholly biocompatible, and also individual atoms within a metabolite are
easily distinguishable by NMR and mass spectrometry.
Stable Isotope Resolved Metabolomics (SIRM) is an
approach that has been developed, which combines the
power of global (untargeted) metabolic profiling with atomresolved tracking of metabolites during metabolic transformations within cells, tissue or whole organisms. The cell
culture, tissue, or organism is provided with a source
metabolite that is enriched at any or all of the atoms with a
stable isotope (like 13 C or 15 N with natural abundances 1.1 %
and 0.37%, respectively), and the products are analyzed by
NMR and MS at different times after treatment. Such
products will include isotopomers, which are isomers having
the same isotopes, but differing in the location of the
isotopes (e.g., 13 CH 3 CH 2 CH 2 CH 3 vs. CH 3 CH 2 13 CH 2 CH 3 ),
and isotopologues, which are sets of isotopomers with the
same mass. With SIRM data in hand, specific isotopomer
and isotopologue distributions in the various product
metabolites can be determined, along with the total amounts
of the metabolites, which together provide detailed information about the relative importance of intersecting and
parallel pathways. For example, lactate can be produced
directly from glucose by lactic fermentation, as well as by
glutaminolysis; the relative contributions from these independent pathways is readily determined from the isotope
distributions in the lactate using either 13 C-enriched glucose
or glutamine as labeled sources. At the same time such
labeling schemes provide simultaneous information about
the flow of carbon through the pentose phosphate pathway,
glycolysis, hexosamine pathway, the Krebs cycle and lipid
biosynthesis among others.
Recent advances in metabolomics technologies, such as
SIRM, which combine the complementary isotope-sensitive
techniques of MS and NMR, enable rapid detection of tens
of thousands of isotopologues and isotopomers representing
thousands of metabolites; however, the necessity for
metabolite identification, quantitative analysis, and interpretation, within the context of relevant metabolic networks,
represents key barriers to the use of this avalanche of
information-rich phenotypic data. In fact, over 50% of
detected metabolites represented by cliques of detected
spectral features remain unidentified in ultra-high resolution
mass spectra. Therefore, the present inventors have developed a system and method that determines the isotoperesolved molecular formula for metabolites detected via sets
of related isotopologues from mass spectra of samples that
have been labeled with specific stable isotopes like 13 C, 15 N,
and 2 H from a given labeling source and/or from natural
abundance.
The presently-disclosed subject matter includes methods
and systems that allow for identification of metabolites that

5

DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as is commonly
understood by one of skill in the art to which the invention(s)
belong. All patents, patent applications, published applications and publications, GenBank sequences, databases, websites and other published materials referred to throughout the
entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there
are a plurality of definitions for terms herein, those in this
section prevail. Where reference is made to a URL or other
such identifier or address, it understood that such identifiers
can change and particular information on the internet can
come and go, but equivalent information can be found by
searching the internet. Reference thereto evidences the
availability and public dissemination of such information.
Although any methods, devices, and materials similar or
equivalent to those described herein can be used in the
practice or testing of the presently-disclosed subject matter,
representative methods, devices, and materials are now
described.
Metabolomics can be described as the study of collections
of metabolites, both intermediate and end products of cellular processes. Living cells are maintained under nonequilibrium conditions, which requires constant input of
energy. The cells must also maintain their infrastructure, and
perform tissue-specific tasks, all of which need energy and
raw material. Metabolism is the set of processes that convert
exogenous compounds to metabolic energy, which drives
biochemical reactions within the cell, maintains homeostasis, provides the means to do work (e.g. contraction, movement, action potentials, secretion and so forth), for cellular
repair, and to divide. Metabolism responds to exogenous
signals as represented by diet and pollutants for example,
and local environments (microenvironment) as represented
by the conditions prevailing outside cells in tissues. As such,
metabolism is a sensitive indicator of pathology, and the
ability to measure global metabolism in quantitative detail is
of fundamental importance in all aspects of biology. Practical examples include prediction and identification of disease state and prediction of response to therapeutics.
Metabolomics tools provides the technical means to carry
out global analyses of metabolism, by identifying and quantifying a large fraction of all of the metabolites present in a
cell, and how they change in response to perturbations
within relevant metabolic networks. Metabolomics therefore
requires high-end analytical instrumentation, including mass
spectrometry (MS).
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are detected using MS. Methods and systems of the presently-disclosed subject matter can involve processing and/or
obtaining MS data. In some embodiments of the presently
disclosed subject matter, the metabolites are identified has
having a particular element-specific molecular formulae
(EMFs). In some embodiments, the metabolites are identified has having a particular isotope-specific molecular formulae (IMFs).
Referring now to the present method with specific reference to the drawings, and in particular FIGS. lA-lC. FIG.
lA is a flowchart that shows an overall high-level method in
accordance with the present invention for identifying an
unknown compound and FIG. lC is a high-level schematic
of a system 100 that can implement method 10. Method 10
incorporates the five (5) main components of the present
method for identifying an unknown compound including
metabolites. Accordingly, FIG. 1B is a high-level schematic
showing how the five main components of method 10
interact to identify an unknown compound. The system 100
comprises a mass spectrometer (MS) 110 associated with a
computer 130 for identifying metabolites in a sample (i.e.
Metabolites 120). Mass Spectrometer 110 generates spectral
data from unknown metabolites 120. The computer 130
analyzes the spectral data using a processor 132, processor
memory 134 and data storage 136. While FIG. lC shows
computer 130 as containing a i) processor 132, ii) processor
memory 134 and iii) data storage 136, each of these three
components can be distributed across a computer network,
processor 132 may comprise multiple processors connected
together, and/or computer memory 134 and data storage 136
may be separate components (e.g. peripherals) operatively
associated with a computer/computer processor.
A first step in method 10 is molecular fragment cache
building (step 20). This includes creating molecular fragments for a given set of isotopes within a mass range (step
21). Next a partial NAP is calculated of reach molecular
fragment using processor 132 (step 22). Further, based on
this calculation, probable molecular fragments are kept for
further analysis (step 23). Molecular fragments are sorted by
mass (step 24). Finally with regard to the molecular fragment cache building (step 20), a binary-like search tree is
generated (step 25) and stored in computer storage 136.
Accordingly, step 20 implements Component 1 and Component 2 of the present method for identifying an unknown
compound as shown in FIG. 1B. The result of all parts of
step 20 is a multi-terabyte molecular fragment cache 30 that
is created in computer storage 136 (FIG. lC).
A list of known and/or possible contaminant ions (step 31)
along with the raw FTMS spectrum (step 32) are converted
and analyzed in step 40 to filter out real spectral peaks from
analytical artefacts, chemical artefacts, and noise. The
resulting real spectral peaks are characterized with respect to
peak m/z, height, and normalized area across raw FTMS
scans. These steps correspond to Component 3 as shown in
FIG. 18.
As one of ordinary skill in the art will appreciate, mass
spectrum data may include artifacts such as contaminate
ions. Accordingly, the present method 10 identifies likely
contaminate ions as will be discussed below in further detail
with regard to contaminate ion identification. Using raw
Fourier transform mass spectrometry (FTMS) and a likely
list of contaminate ions, peaks are characterized and artifact
peaks removed (FIG. lA, step 40 and FIG. 1B, Component
4) using the multi-terabyte molecular fragment cache 30 in
computer storage 136. A search of possible IMFs for each
non-artifact peak is conducted using processor 132 and
computer memory 134 (step 50). Subsequently, IMFs are

organized into possible EMFs (step 60). EMFs are selected
by processor 132 that exceed a predetermined or given
statistical significance (step 70). Based on this, a list of
detected EMF caches are identified (step 80). This list of
detected EMF caches allows one to identify the specific
actual elemental molecular formula for the unknown compound such as a metabolite. Accordingly, the present method
can be used to identify compounds such as the elemental
molecular formula for an unknown metabolite.
In some embodiments, methods of the presently-disclosed
subject matter involve assembling a large sorted cache of
plausible molecular formula fragments. Such assembly can
involve use of metabolite bonding pattern rules for elements
in the cache. For example, the number of hydrogens is
bounded by the number of carbons and nitrogens. Such
assembly can also involve calculating a natural abundance
probability (NAP) of isotopes of non-labeling elements
(e.g., 13 C has a natural abundance of 1.1%). In some
embodiments, the NAP can be calculated using the following formula: xxx
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This formula can be used to calculate the NAP for specific
isotopically-resolved molecular formulas. In the case where
a specific isotope(s) comes from a labeling source, a relative
NAP is calculated where that isotope's contribution to the
element's probability (PE) is omitted. For isotope combinations for elements containing 3 or more isotopes, one of
which is labeled, a relative NAP can be calculated using the
remaining isotopes else the relative NAP is set to one.
The set of isotopes excluded from the NAP calculation
depends on experimental conditions (e.g., 13 C can be used as
a label/tag, but also has a natural abundance of 1.1 % and will
be present even when not used as a label/tag).
In some embodiments, methods of the presently-disclosed
subject matter involve calculating a set of possible isotopically-resolved molecular formulae for each detected isotopologue, within a specified accuracy tolerance. Such isotopologues can be detected, for example, by a particular m/z
ratio peak by MS. Such calculation can involve assembling
specific isotopically-resolved molecular formulae, and filtering such formulae, for example, using calculated NAP,
calculating m/z matching probability, a statistical measure of
how well the molecular formula matches the m/z ratio, and
using metabolite bonding pattern rules.
In some embodiments, methods of the presently-disclosed
subject matter involve identifying a metabolite isotopo!ague-offset clique, which is a clique of isotopologue and
offset peaks associated with a specific elemental molecular
formula. Such identification can involve identifying compatible isotopically-resolved molecular formulae for pairs of
isotopologues, by comparing their sets of isotopically-resolved molecular formulae and identifying an intersection
between the sets. Each intersecting pair of complementary
isotopically-resolved molecular formulae that correspond to
the same elemental molecular formula and have equal
numbers of labeling isotopes are statistically evaluated.
Such evaluation can make use of both m/z matching probabilities and calculation of a log-ratio match probability,
which is a log ratio of isotopologue peak intensities statis-
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tically compared to the log ratio of each isotopicallyresolved molecular formula NAP. Each compatible intersecting pair of isotopically-resolved molecular formulae
represents evidence for specific elemental molecular formulas in a mass spectrum. Specific elemental molecular formulae are identified by statistically evaluating the sum of
compatible intersecting pairs of isotopically-resolved
molecular formulas that support the same elemental molecular formula.
In some embodiments, methods of the presently-disclosed
subject matter involve identifying super cliques, with interclique differences in elemental and isotope-specific molecular formulae, in the mass spectrum. Such identification can
involve comparing a pair of detected metabolite isotopologue-offset cliques using a matrix of log intensity ratios.
Such differences in elemental and isotope-specific molecular
formulae can reflect additions of known tags and/or adducts
to specific metabolites represented by the elemental molecular formula of the base clique.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, and in some embodiments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
As used herein, "optional" or "optionally" means that the
subsequently described event or circumstance does or does
not occur and that the description includes instances where
said event or circumstance occurs and instances where it
does not. For example, an optionally variant portion means
that the portion is variant or non-variant.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the present invention.

bination of bioinformatic, biostatistical, and systems biochemical tools for the analysis of large metabolomics
datasets. This integrated set of analyses will have broad
application from the discovery of specific metabolic phenotypes representing biological states of interest to a mechanism-based understanding of a wide range of specific biological processes (cell growth, apoptosis, differentiation,
nutrient specialization, symbiosis, etc.) with particular metabolic phenotypes.
Example 1. Develop tools for raw data analysis, error
analysis, and quality control of SIRM data. The present
inventors contemplate standardized procedures and tools for
analyzing MS data that include peak assigmnent, metabolite
identification, quantification, error analysis, and quality control. These tools will automate the detection and assignment
of isotopologues from ultra-high resolution/accurate MS
histograms. Emphasis is put on the development of methods
for detecting and facilitating assignment of unidentified
metabolites, as well as error analysis of isotopologue intensities. The new methods are truly innovative since they
utilize the combined advantages of stable isotope labeling,
new chemoselective probes being developed by collaborators, ultra-high resolution/accurate MS, allowing better integration with other sources of data, especially NMR isotopomer-specific data. The present inventors are also
leveraging metabolite and spectral information in public
databases to facilitate assignment via functional group and
substructure searches.
Develop clique-based methods for identifying FT-MSobserved metabolite isotopologues. CREAM has implemented, in the program PREMISE [5], an algorithm for
automated assigmnent of compounds utilizing the ultra-high
resolution and mass accuracy capability of the FT-MS and
has created a database of known metabolites with their exact
masses calculated to 6 decimal places (accuracy and routine
resolution of m/Am=400,000 @ 400 m/z). This approach,
based on a single monoisotopic peak from FT-MS data, is
limited both by the spectral signal-to-noise ratio and by the
reliance on a database of known metabolites. A more robust
approach is to use a clique of related isotopologue peaks
(e.g. Mo to Ml 7 of UDP-GlcNAc) to detect metabolites.
This approach greatly reduces the false positive rates without using high signal-to-noise cutoffs, as the chance of
multiple noise peaks being correlated in an isotopologueoffset clique becomes infinitesimally small with increasing
clique size. Also, the detection of a self-consistent clique
reduces the need for a metabolite database in the initial
detection. Furthermore, detecting all metabolite cliques
from an FT-MS spectrum is computationally very similar to
the classical problem of listing all maximal cliques in a
graph.
However, many algorithms that solve this problem require
exponential computational time for their worst-case execution [11, 12]. To address these computational issues, the
present inventors have designed an algorithm that makes the
graph representation very sparse, allowing the use of optimal "maximal clique" methods that sidestep the computationally challenging issues inherent in classic maximal
clique detection algorithms [11, 13]. Many of the computationally expensive steps of the algorithm are easily parallelizable, allowing full use of newer high-multicore (> 100
cores) computer systems. The algorithm exploits the ultrahigh mass accuracy (routinely 5_1 ppm) and resolution
(400,000 m/Am) of the FT-MS [14] that can distinguish
mass differences between isotopologues with the same
nominal mass but differing isotope counts. At this resolution,
a unique or near-unique isotope-specific molecular formula
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(e.g. 13 C 5 12C 1 1 H 12 16 0 6 for the MS 13 C isotopologue of
glucose) can be directly calculated from the mass measured
when limited to expected elements in metabolites. In the
algorithm, the list of possible isotope-resolved molecular
formulae is reduced to the list of elemental (non-isotope
resolved) molecular formulae. Each pair of peaks within a
sliding window of n Da of each other is then compared to see
if their lists of elemental molecular formulae intersect. In
this case, n is limited by the number of non-labeling isotopes
of a particular labeling element present in the isotopespecific molecular formula. The intersection test creates a
very sparse graph.
Detected metabolite isotopologue-offset cliques represent
a group of isotopologues due to natural abundance isotopic
distribution and/or enrichment from metabolic tracers.
Quantitative analyses of isotopic enrichment require correction for the natural abundance of the isotopes (e.g. 1.11 % for
13
C) before application in the reconstruction of relevant
metabolic networks (cf. 1.13.4). The present inventors have
designed, implemented, and parallelized algorithms based
on analytical solutions that correct for the effects of isotopic
natural abundance [3, 15] and will apply them as a final
quality control assessment for detecting metabolite isotopologue-offset cliques (cf. 1.13.2.6).
Pairwise comparisons of detected metabolite isotopo!ague-offset cliques will be used to identify super-cliques
across multiple related FT-MS histograms (e.g. ±different
chemoselective (CS) tags, ±CS isotope encoding, ±adducts,
or ±labeled tracers), with inter-clique differences in both
elemental (e.g. C6H1206) and isotope-specific molecular
formulae. These differences reflect additions of known CS
tags, adducts, or labeled atoms to specific metabolites represented by the monoisotopic mass or base clique. Reducing
computation to pairwise clique comparison of elemental and
isotope-specific molecular formulae is both very efficient
and easily parallelizable. Thus, super-clique detection will
identify a list of functional groups or enriched isotopologues
associated with each base clique.
Develop methods to deal with unidentified metabolites.
There are two kinds of unidentified metabolites in these
datasets. The first is an assigned metabolite that has not been
placed into known metabolic networks. The second kind is
a detected compound where only its molecular formula and
certain chemoselected functional groups have been
assigned. To address both kinds of unidentified or partially
assigned metabolites which make up a majority of current
SIRM and other metabolomics datasets, the present inventors contemplate the development of methods that map
structurally similar compounds onto known metabolic networks, starting with versions available from KEGG Pathway
[31], to determine hot spots of similarity (clusters) and
calculate a probability or likelihood of placement. Metabolic
network correlations between similar compounds represent
hypotheses for where newly discovered metabolites may fit
within metabolic networks of interest. In this regard, tools
have been implemented that download the metabolic networks in KEGG Pathway into a local MySQL database
which will be converted into a SQLite database. This
mapping of compounds can be done for similar matches
from HMDB and KEGG Compound or exact matches from
ChemSpider.
This mapping onto metabolic networks creates an additional filter on ChemSpider results that removes organic
compounds with no significant similarity score to compounds in the metabolic networks and thus are not expected
to exist in general cellular metabolism. Also, mappings will
be very sparse with respect to the metabolic network, except

in rare cases that a metabolite is very similar to a common
cofactor or coenzyme like ATP. Therefore, a simple greedy
node inclusion algorithm should suffice to identify hot spots.
More sophisticated clustering methods will be investigated
if needed. Ranking of hot spots will be based on a scoring
method like the summation of node similarity multiplied by
the highest similarity score in the hot spot. The centroid node
and size of the hot spot may be additional useful features to
calculate. Furthermore, this general methodology should be
amenable to correlated cliques of unidentified or partially
identified metabolites and not just a single unidentified
metabolite. Correlated cliques of metabolites will be derived
from covariance analyses across a time series of MS experiments (cf. 1.13.3.2).
However, there is a general assumption made by the
above approach: unidentified metabolites are structurally
similar to metabolites in known metabolic networks. This
may not be true in some instances. An alternative approach
is to take a correlated clique of unidentified metabolites and
i) identify exact matches in ChemSpider for each unidentified; ii) structurally compare these exact matches between
the unidentified; and iii) find the most common substructure
that best spans the clique of unidentified metabolites. This
refinement into a common substructure may improve mapping onto metabolic networks, especially when combined
with additional correlation data. At the very least, this
approach provides hypotheses of the chemical structures or
substructures of the unidentified. Finally, open source tools
like Cytoscape [32, 33] will be used to generate graphics that
visualize the results from these approaches. Cytoscape is a
general tool for visualizing networks and other graphs and is
an excellent choice for visualizing hot spots of similarity
within metabolic networks. In addition, common substructure similarity across a clique of metabolites can be represented as a graph using this tool.
Develop dataset-based and clique-based error analyses for
quality control and evaluation of error propagation. The
purpose of the above described methods is to reduce raw
spectroscopic data in fully and partially identified lists of
metabolites, with their isotopomer/isotopologue intensity
distributions quantified, especially across a series of related
spectra and histograms. Since FT-MS histograms typically
take only 5 minutes to collect for a dataset containing tens
of thousands of isotopologue peaks, it is relatively straightforward to measure and calculate both absolute and relative
peak intensity variance across analytical replicates. From a
quality control perspective, an abnormally high analytical
replicate variance can indicate problems with the analytical
platform or sampling handling. Both possibilities should be
tested, especially when low signal-to-noise ratios are
detected. After accounting for analytical variance, the
remaining variance across biological replicates is often
interpreted as being of biological origin, especially when
mixed model methods are utilized [34].
However, thanks to the presence of isotope labeling due
to natural abundance (NA), correction of natural abundance
can also be used to calculate error at the level of a specific
detected metabolite isotopologue-offset clique. These 13 C
and 15 N natural abundance correction algorithms have been
implemented based on the present inventors' derived analytical solution [3-5]. From rigorous tests on simulated
datasets, these iterative correction algorithms propagate only
half of the error expected from the non-iterative analytical
solution. Moreover, with reference to FIGS. 10 and 11, due
to the excellent parallelized design and optimization of these
algorithms, NA correction in a typical isotopologue dataset
(50000 peaks organized into 9066 metabolite isotopologue-
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offset cliques) dropped from over 600 seconds for a single
core to less than 50 seconds with multiprocessing for 12
cores on a Linux machine with dual Intel Xeon Processors
X5650 (each processor has 6 cores). Because of this parallelized improvement in running time, a clear and computationally practical path is seen for estimating various types of
systematic error via simulation for each analytical replicate
at the level of each detected and identified isotopologue.
This is done by a comparison of varied amounts of simulated
systematic and nonsystematic error between metabolite isotopologue-offset cliques within a single analytical replicate.
When combined with an analysis across multiple analytical
replicates, total replicate variance can be separated into
systematic and nonsystematic components. This approach
could allow a very significant correction in systematic error
and a large reduction in analytical replicate variance and in
propagated error in downstream analyses.
Example 2. Develop basic biostatistical analysis of
refined data. The present inventors are developing basic
biostatistical analyses and visualizations of SIRM datasets
that: i) support the optimal design of SIRM-based experiments with sufficient statistical power and ii) promote sound
metabolic interpretation of SIRM data. Specifically, statistical power estimation tools for common SIRM experimental designs are contemplated, especially matched case-control paired experimental designs, which have better
statistical power. More advanced statistical and machine
learning methods will also be used to assess sample discrimination and classify samples with respect to biological
states and conditions of interest.
Correlated metabolite clique analysis. Again using optimal "maximal clique" identification methods [37, 38], the
present inventors will identify positively correlated sets of
isotopologues and isotopomers and metabolite-specific
chemical moieties representing relative flux. The focus on
correlated metabolite cliques is pragmatic for maintaining a
low false discovery rate (FDR) [39, 40] and preventing type
I errors, which is achieved by using the correlated cliques to
estimate covariance, effectively reducing the dimensionality
of the datasets. This is especially important for subsequent
analyses that deal with sample classification and mechanism-based hypothesis generation. When matched casecontrol datasets are being analyzed, the correlation will be
calculated using the difference in the normalized isotopologue intensity or chemical moiety parameter value. The
covariance error matrix will be calculated from a set of
analytical replicates and this matrix will be used as a
weighting factor to compensate for the non-independent
error expected with these highly correlated datasets [41].
The significance and statistical power of correlated metabolite cliques will be evaluated with respect to intra-cliquecorrelation, correlation to specific metabolic pathways, and
effect sizes (for matched case-control datasets). Criteria will
be used based on a combination of these measures along
with a minimum clique-size to limit which cliques are
accepted as meaningful metabolic phenotypes and used to
build classification models. The criteria needed for a desired
false discovery rate (FDR) will be empirically estimated via
a series of simulations where a large number of random
datasets are created and analyzed using expected correlations from known metabolic pathways, the levels of variance
in experimental datasets, and the size of experimental datasets. This approach has been found to be valuable for
significance testing in identifying relevant GO terms [42].
General statistical analysis and visualization. Packages in
the R statistical programming language are currently used
for common statistical analyses such as mean, median,

standard error, range, 95% CI, t-test in its various variants,
ANOVA, general linear regression, logistic regression, and
statistical power calculations. To identify significant differences, the ratio (using threshold ratio) of the control and
perturbed groups will be compared using Fisher's Exact test
[43] and then logistic regression will be used to model and
test the effect of other covariates such as age and gender.
Metabolites will also be compared using GLM procedures,
including covariates such as age, gender, polyploidy where
relevant. Correlation clustering methods are particularly
good at handling high dimensional datasets [44].
A variety of tools available in Python and Rand elsewhere
are used to visualize datasets in a variety of ways. Principal
Components Analysis (PCA) is used to visualize information content and its dimensionality with respect to variance.
Partial least square discriminant analysis (PLS-DA) and
newer OPLS-DA methods [45] will be used to assess class
separability of samples, even if implementation of a version
of OPLS-DA is required (currently no released R or Python
package appears available). 3D data displays and heat maps
will be used to visualize correlations among detected isotopologues and categories of samples as derived from various
clustering methods. The new R-based tool NeatMap that
generates heat maps from non-clustering methods like PCA
[46] will be used, allowing side-by-side comparison with
results from clustering methods. Open source tools like
Cytoscape [32, 33] will be used for network visualization.
Construction of classification models. Using both refined
metabolite data and accepted metabolite cliques, prediction
and classification models will be built and evaluated using a
variety of model building methods. Following a visual
review of the data with PLS-DA and OPLS-DA [47, 48],
machine learning methods will be used, including random
forest [49, 50] and support vector machines with kernel
selection [51, 52]. These machine learning methods are
better at dealing with nonlinear correlations that may be
present in a dataset. Moreover, random forest excels at
multi-category classification. Various PLS-based, kernelbased OPLS [53], and machine learning methods are implemented as packages in R.
Example 3. Develop metabolic network reconstruction,
moiety deconvolution tools, and omics-level data integration
for mechanism-based analysis of biological processes. The
present inventors will build upon manual approaches that
interpret SIRM data within the context of relevant metabolic
networks and facilitate mechanism-based analysis of correlated metabolites. Specifically, tools are being developed
that will automate reconstruction of metabolic networks that
are relevant for the interpretation of SIRM time-series
experiments and SIRM datasets will be deconvoluted to
determine relative pathway fluxes through these networks.
The resulting pathway-specific information will serve as a
point of integration and cross-validation with genomics,
transcriptomics, and proteomics data, enabling interpretation of metabolic phenotypes within the context of specific
metabolic and signaling pathways that are part of biological
processes of interest. This context-specific interpretation
will generate mechanism-based hypotheses and additional
tools for their testing.
The present inventors are developing a combination of
methods that will: i) analyze the relative isotope incorporation and perturbation of correlated metabolites of interest
derived from raw data analyses and biostatistical analyses
described above with respect to specific pathways within
metabolic networks; ii) integrate this pathway-specific
metabolomics information with genomics, transcriptomics,
and/or proteomics data; and iii) facilitate relative flux inter-
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pretation and full metabolic flux analysis of moiety deconvoluted data within the context of specific metabolic and
signaling pathways within biological processes of interest.
The heart of these new methods are the moiety modeling
methodologies and tools [1, 10] designed to deconvolute
SIRM datasets. Non-steady-state experimental conditions
are an unavoidable reality for most eukaryotic SIRM datasets, since true isotopic steady state is difficult or impractical
to achieve, especially in animal systems. The moiety modeling methods are designed to handle the specific information-rich, isotopic non-steady-state conditions of these
experiments. From these analyses, the present inventors can
derive pathway-specific relative flux and perturbation detailing the functional significance of particular metabolic phenotypes of interest. Application of these methodologies
entails the following:
Integration and refinement of organism-specific metabolic
information.
Moiety model creation.
1. Moiety model optimization and selection.
2. Quantitative pathway analysis and relative pathway
flux interpretation.
3. Integration with genomics, transcriptomics, and/or proteomics data.
The approach is to extract the necessary parts of metabolic networks according to given tracer inputs. For any set
of input tracers, first their transformation pathways are
selected and defined as the initial network. The fates of
individual atoms are traced through the initial network and
major downstream pathways are included stepwise. This
process is performed iteratively so that the network size is
kept within a computationally feasible scale. Here, the
approach with a combined NMR and FT-ICR-MS SIRMbased study on the biosynthesis of UDP-GlcNAc is illustrated[!] (cf. FIG. 12), which is a key donor for N- and
0-linked protein glycosylation [54-56]. UDP-GlcNAc has a
unique NMR spectrum that is resolved from UDP-GalNAc
and other UDP sugars. Based on the individual components
of UDP-GlcNAc (FIG. 13b) and their known biosynthetic
pathways (FIG. 12), a chemical substructure model (FIG.
13a) was constructed to enable non-steady state modeling of
13
C incorporation from labeled glucose into UDP-GlcNAc.
The possible 13 C labeled isotopologues (cf. FIG. 13a)
deduced from the pathways and FT-ICR-MS data were then
used as model parameters in a combined simulated annealing/genetics optimization algorithm implemented in the program GAIMS [1]. Fitting these model parameters to the 18
observed FT-ICR-MS 13 C-only isotopologue series (mO to
mO+l 7, FIG. 13c), while accounting for the 13 C natural
abundance, defined relative flux through multiple connecting pathways between glucose and UDP-GlcNAc (FIG. 14),
without the prerequisite for isotopic steady-state [1 OJ. Moreover, the relevant network reconstruction, moiety deconvolution, and moiety model selection simplifies and frames the

metabolic flux problem that can be accurately addressed by
a isotopic non-steady-state full metabolic flux analysis [5759].
Integration and refinement of metabolic information. For
the tracer-based data analysis needs, web-based tools are
being developed that: i) access relevant metabolite, metabolic pathway, atom-resolved mappings, subcellular localization, and tissue-specific gene expression information
from public databases and ii) combine and refine this
information for mapping to relevant parts of the targeted
metabolic network. These web-based tools will extract
metabolic pathway information from a variety of sources
including: KEGG Ligand for atom-resolved metabolic pathways for over a thousand organisms [26]; ARM for the most
complete atom-resolved metabolic pathways in E. coli [60];
MetaCyc family of databases for the most complete metabolic maps [61, 62]; and Reactome for human subcellularlylocalized metabolic pathways [63, 64]. With the use of the
Django web framework, a database schema for an enhanced
atom-resolved metabolic network based on KEGG Ligand
has been implemented and is now being testing via scraping,
processing, and populating with data from KEGG Ligand.
This implementation allows easy portability to several different physical databases including MySQL, PostgreSQL,
and SQLite, which have been directly tested during the
evolution of this database schema.
However, the real problems are in obtaining useful and
reliable subcellular localization annotation. Currently, the
metabolic pathway databases link back to Uniprot [65, 66]
which aggregates annotation at the "protein" record. Table 2
represents a preliminary analysis of the Swiss-Prat version
(downloaded Mar. 5, 2012) of Uniprot showing human
enzymes organized by major EC number group versus
subcellular localization. However, many genes are transcribed into multiple RNA transcripts which encode different isoforms of a protein. Uniprot stores only one composite
"protein" record for almost all isoforms of a particular
protein gene product. All the annotations for each isoform
are simply aggregated under the single "protein" record with
the relationship between isoform and annotation lost. This is
a problem since the most reliable annotations are in the
manually curated and reviewed Swiss-Prat. Now EMBLENA [67-69] has annotations associated at the RNA transcript level; however EMBL-ENA includes less reliable
automatic annotations. In fact, the EMBL-ENA is translated
into the TrEMBL version of Uniprot which also has annotations aggregated in the "protein" record. Since TrEMBL
has Swiss-Prat annotations removed to prevent duplication
of annotation, the present inventors will filter EMBL-ENA
against Swiss-Prat in order to produce a dataset of reliable
subcellular localization annotations associated directly with
its RNA transcript. This will be invaluable for later integration with transcriptomics and proteomics datasets.
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TABLE 2
Human enzymes organized by major EC# group & subcellular
localization annotation from Swiss-Prot.

EC awosouelauti
3
2
3
4
5
6

9
0
0
6

Golgi
7
195
51
2
3
9

Lysosome Cytoplasm
6
7
68
0
0
9

113
473
414
29
31
153

Secreted

Cell Membrane

37
37
244
2
3

49
292
308
22
8
41

Cytoplasmic
Endoplasmic
Vesicle
Nucleus Reticulum

Peroxisome

Mitochondrion

57
360
378
12
21
90

27
10
9
6
6
7

118
130
82
16
12
58

20
19
0
10

116
137
89
7
19
27
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Protein-protein interactions are another important type of
annotation in metabolic networks and especially useful in
deducing nonsymmetric catalysis of symmetric molecules,
which is common in multienzyme complexes. However,
protein-protein interactions are not nearly as conserved as
enzymatic function and are much harder to predict. Potentially useful protein-protein interaction databases like iPfam,
PIBASE, DOMMINO, and MIPS [70-73] and various prediction methods are being investigated [74-79]. Also, new
semantic relationships added to Gene Ontology [80] will aid
in combining localization with cellular component annotations [81].
Develop atom-resolved pathway tracing and metabolic
network reconstruction methods for moiety model creation.
The present inventors are drawing on classic graph theory as
a starting point for developing algorithms that trace relevant
short paths through metabolic networks from labeled tracers
to enriched metabolite isotopologues and isotopomers. Both
k-shortest paths [82] and k-shortest simple paths (loopless)
[83] algorithms will be employed to trace isotope from the
labeling source to every labelable atom in the assigned
metabolite. Preference is given to paths that combine the
largest co-tracing of atoms, which represent the flow of
specific functional moieties through the metabolic network.
Since the metabolomic database in KEGG for any given
organism is incomplete, tracings will be used from other
organisms (1000 in KEGG) as hypothetical pathways. The
metabolites and labeling patterns assigned from FT-MS and
NMR time series data will be used to verify or refute all
plausible hypothetical pathways. Finally, detected unidentified metabolites will be placed within the reconstructed
metabolic networks based on: their molecular formulae/
functional groups (from FT-ICR-MS), identified substructure (NMR), time series correlations with known metabolites, and labeling patterns.
With the metabolic information described above aggregated into an atom-resolved metabolic network specific to
the organism of interest, the methods being developed will
be able to trace groups of atoms or chemical moieties from
a labeled source molecule to an observed metabolite through
numerous metabolic transformations in cellular metabolism
of the appropriate organism. As with any complex network,
many different tracings are possible. Currently, models are
described manually using a moiety model description language [1]. Web-based tools are being developed to aid in
creating moiety models. These tools will also help generate
related sets of plausible moiety models from relevant metabolic pathway information. Model creation requires four
separate steps: i) search for relevant plausible metabolic
pathways as described above; ii) identify traceable chemical
moieties; iii) identify chemical moiety labeling states (i.e.
possible levels of stable isotope labeling in the moiety); and
iv) generate model description. Each step will be linked by
common file formats and data structures, like the chemical
moiety model description language (CMMDL), composed
of nested name-value pairs describing traceable chemical
moieties and their possible labeling states. The CMMDL
parser will be expanded to simultaneously handle multiple
metabolites with cross-dependencies between moiety substructures as the moiety model creation tools are developed
into fully automated versions. These improvements will
eventually allow simultaneous analysis of hundreds or even
thousands of metabolites.
Moiety model optimization and selection. A parameter
optimization tool has been developed that uses a simulated
annealing genetic algorithm to optimize chemical moiety
state parameters based on experimental data for a given

chemical moiety model description [1]. A specific application of this tool is illustrated in FIG. 13. Since optimizations
are normally repeated many times, this tool can be run on a
Linux cluster in a distributed fashion via the use of standardized queue submission protocols (openPBS/TORQUE).
These facilities will be expanded to handle the parameter
optimization of models involving multiple metabolites. Furthermore, hierarchical and jack-knife approaches will be
developed when optimizing moiety state parameters of
many metabolites. Both approaches begin with the parameter optimization of individual and small correlated sets of
metabolites (correlated metabolic cliques) before optimization across larger sets of parameters. These approaches are
needed to efficiently optimize parameters for thousands of
metabolites simultaneously.
A robust model selection method has also been implemented using the Akaike information criterion (AIC) [84]
applied to average optimized parameter values [1]. Highly
plausible models and often a unique model are selected from
a large possible set using the SIRM time-course data. This
allows the SIRM experimental data to test hypotheses of
metabolic pathways made during moiety model creation,
filling in gaps in current organism-specific metabolic information. Although the preliminary results with this model
selection method applied to single metabolite models indicate a very robust selection method, harder problems could
arise when selecting models involving multiple metabolites.
Anticipating cases where multiple models are selected,
additional model comparison tools will be developed that
will identify common components between chemical moiety
models, which will demonstrate high confidence in these
components. Furthermore, it will be necessary to apply
model selection earlier in the model creation and optimization steps to prevent a combinatorial explosion in the
number of multiple metabolite models that need to be tested.
Very low probability branches in the model search tree can
be trimmed to limit this combinatorial explosion. Moreover,
submode! selection and submode! likelihood functions may
be required to direct model creation when all possible
models cannot be enumerated.
Quantitative pathway analysis and flux modeling. Determining the time evolution of moiety state parameters provides the means to determining pathway fluxes. From this
analysis, the present inventors know the relative substructure fluxes from the labeling source to the metabolite
through atom-resolved metabolic pathways identified from
model selection. By comparing these multiple pathways
from labeled source to detected metabolites the following
can be identified: i) localized pathways in common; ii)
branch points in these pathways, which often represent sites
of regulation; and iii) the relative fluxes through these
branches. Changes in these relative fluxes would indicate a
change in the regulation at these branch points and provide
significant mechanistic understanding for representative
metabolic phenotypes.
Facilitating 'omics' integration and mechanism-based
hypothesis generation. Perturbed pathways derived from
correlated metabolite cliques and changes in relative flux
will become a common point of integration and crossvalidation with other omics-level coupled datasets that are
obtained. As an analytical cross-validation with metabolomics, this approach is statistically more powerful than
pathway enrichment analysis strategies [85, 86]. Specific
protein gene products identified by this cross-validation with
omics-level datasets under perturbed conditions become
potential hypotheses for the perturbation mechanism. To
complement this coupled-experiment approach, relevant
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omics-level datasets already in the public repositories like
genetic variations in dbSNP [87], transcriptomics data in
GEO [88, 89], and proteomics data in PRIDE [90, 91] will
be analyzed. GEO search methods and dbSNP search methods are being explored.
Alternative Approaches. One problem already mentioned
is the incomplete information on metabolic networks of
various organisms and their compartmentation. Tools will be
developed that can generate more complete metabolic pathways from other organisms and validate these hypothetical
pathways using SIRM experimental data. Another known
problem is that not all metabolites are in the databases. The
combined molecular formula, functional group, and substructure information will be used to search ChemSpider
(http://www.chemspider.com/) for candidate structures. Further analysis of NMR data and MS/MS fragmentation patterns can be used to refine this list of candidates. Another
potential issue is the combinatorial explosion in chemical
moiety model creation and optimization involving large
numbers of metabolites. This can be addressed using a
combination of approaches: i) use submode! optimization
and selection to eliminate highly improbable models; ii) use
metabolic clique analysis, hierarchical, and jack-knife
approaches to direct model optimization and selection; and
iii) distribute the parameter optimization across a large
computer cluster (e.g. University of Louisville CRC).
Another potential issue is building good classification models. A variety of statistical and machine learning methods
can be used to find the best classifier and identify key
metabolic cliques. To handle non-independent error in the
datasets and the covariance in time series, a set of analytical
replicates will be used to calculate an error covariance
matrix. A GEE model will be used to deal with issues of
covariance in the time series [92] [93].
Example 4. Metabolite Identification in Ultra-high Resolution Mass Spectrometry. The present inventors have developed and prototyped a system and method that determines
the isotope-resolved molecular formula for metabolites
detected via sets of related isotopologues from mass spectra
of samples that have been labeled with specific stable
isotopes like 13 C, 15 N, and 2 H from a given labeling source
and/or from natural abundance.
The approach requires multiple components to overcome
the inherent combinatorial problem related to finding the
correct isotopically-resolved molecular formula (i.e.
12
C 5 13 C 1 1 H 12 16O 6 versus C 6 H 12 O 6 ) out of roughly 1.1 quadrillion (1.lxl0 15 ) of possible combinations that must be
searched for each isotopologue with a molecular mass of
less than 2000 Daltons. The components include: i) mathematical formulas implemented in algorithms that calculate
natural abundance probabilities for isotopes of non-labeling
elements; ii) large sorted caches of molecular formula fragments for a subset of isotopes being searched; iii) algorithms
that characterize peaks from raw a raw spectrum and separate sample-specific peaks from various spectral artefacts
seen in ultra-high resolution Fourier transform mass spectra;
iv) algorithms that create sets of possible isotopicallyresolved molecular formulas by iteratively searching the
molecular formula caches, combining with additional isotopes and molecular fragments, and statistically filtering
resulting isotopically-resolved molecular formulas; v) algorithms that identify metabolite cliques and super-cliques of
isotopologues via the comparison of sets of possible isotopically-resolved molecular formulas from different isotopologues that identify compatible element-resolved molecular
formulas in a statistically robust manner. These components
will now be discussed in more detail.

Component 1. Mathematical Formulas Implemented in
Algorithms that Calculate Natural Abundance Probabilities
for Isotopes of Non-labeling Elements.
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The above equations describe the calculation of the natural abundance probability (NAP) for specific isotopicallyresolved molecular formulas. In the case where a specific
isotope(s) comes from a labeling source, a relative NAP is
calculated where that isotope's contribution to the element's
probability (PE) is omitted. For isotope combinations for
elements containing 3 or more isotopes, one of which is
labeled, a relative NAP can be calculated using the remaining isotopes else the relative NAP is set to one.
Component 2. Large Sorted Caches of Molecular Formula
Fragments for a Subset of Isotopes being Searched.
The problem of searching for probable isotopically-resolved molecular formulas is a huge combinatorial problem
that becomes intractable on even large supercomputers for
molecular masses over 500 Daltons. In order to make this
problem tractable, one must build a large sorted cache of
plausible molecular formula fragments using the NAP from
Component 1 and metabolite bonding pattern rules for the
elements in the cache. The cache reduces the molecular
formula search time by a ratio of the time to build the cache
(typically >10,000 CPU hours) versus the time it takes to
search the cache (i.e. milliseconds or better). An example
metabolite bonding pattern rule is the number of hydrogen
atoms in a molecular formula is bounded by the number of
carbon and nitrogen atoms in the molecular formula.
Component 3. Peak Characterization and Detection of
Artefactual Peaks
Detected peaks within spectra collected from Fourier
transform mass spectrometers have a variety of data quality
issues including m/z peak shifting (FIG. 2), inconsistency in
peak heights and areas (FIG. 3), and the presence of artefactual peaks. These data quality issues arise from: i) limitations in digital resolution (FIG. 4); ii) problems with
scan-level consistency (FIG. 5); and iii) Fourier transformbased artefacts (FIG. 6), and iv) the presence of contaminants. However, standard peak picking methods that average
across scans create huge data quality issues. Therefore, an
integrated procedure using a combination of new scan-level
peak characterization methods along with artefact peak
detection methods are required to derive high quality peak
characteristics associated with specific isotopologues. Peak
characterization at the scan-level is implemented by removing noise peaks per scan, corresponding peaks across scans,
and performing normalization of peak heights/areas across
scans. The resulting correspondence peaks are used to derive
high quality peak heights and areas (FIGS. 7 and 8) while
removing many of the high peak density artefacts present
but inconsistent at the scan-level. Separate high peak density
analyses and contaminant detection will remove or mark the
remaining artefactual peaks. A set of contaminant molecules
can be based on expected contaminate molecules from the
plastics and solvents used in sample preparation including
polymers like polyethylene glycol (PEG) and polymer detergents like triton X-100 or derived from quality control
samples directly. A difference matrix generated from this list
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of expected molecules is compared to the difference matrix
tification of both cliques and super-cliques of isotopologue
generated from the peak list derived from a mass spectrum.
peaks associated with a specific metabolite or a set of
Rows between the two matrices with a statistically signifimetabolite isomers. Also, this approach is applicable to a
cant number of differences that match are used to assign
directed search of known elemental molecular formulas by
expected contaminant peaks and derive offsets present in the 5 building an isotopically-resolved cache (Component 2) for
spectrum.
these known elemental molecular formulas. And this
Component 4. Algorithms that Create Sets of Possible
approach is applicable to the analysis of tandem mass
Isotopically-resolved Molecular Formulas by Iteratively
spectroscopic (MSn) data, where the set of possible isotoSearching the Molecular Formula Caches, Combining with
pically-resolved molecular formulas of specific fragment
Additional Isotopes and Molecular Fragments, and Statisti- 10
isotopologues are statistically intersected with the set of
cally Filtering Resulting Isotopically-resolved Molecular
possible isotopically-resolved molecular formulas of the
Formulas.
parent isotopologue.
Each isotopologue is identified by a peak with a specific
Included with this disclosure is an Appendix which
mass to charge ratio (m/z ratio) position in the ID mass
spectrum. The peak also has an intensity related to the 15 includes previous U.S. Provisional Patent Application Ser.
No. 62/187,901.
number of ions physically detected in the mass spectrometer.
All publications, patents, and patent applications menFor each isotopologue, a set of possible isotopically-retioned
in this specification are herein incorporated by refsolved molecular formulas are calculated within a specified
erence to the same extent as if each individual publication,
accuracy tolerance using Component 2 to build specific
isotopically-resolved molecular formulas and that are then 20 patent, or patent application was specifically and individually indicated to be incorporated by reference.
filtered against the NAP from Component 1, a statistical
measure of how well the molecular formula matches the m/z
It will be understood that various details of the presently
ratio (m/z matching probability), and metabolite bonding
disclosed subject matter can be changed without departing
pattern rules.
from the scope of the subject matter disclosed herein.
Component Sa. Algorithms that Identify Metabolite 25 Furthermore, the foregoing description is for the purpose of
Cliques of Isotopologues Via the Comparison of Sets of
illustration only, and not for the purpose of limitation.
Possible Isotopically-resolved Molecular Formulas from
Different Isotopologues that Identify Compatible ElementREFERENCES
resolved Molecular Formulas in a Statistically Robust Manner.
30
Throughout this document, various references are menA pair of isotopologues are compared via an intersection
tioned. All such references are incorporated herein by refbetween their sets of isotopically-resolved molecular forerence, including the references set forth in the following
mulas that identify compatible isotopically-resolved
list:
molecular formulas. Each intersecting pair of complemen1. Moseley, H. N. B., R. M. Higashi, T. W.-M. Fan, and A.
tary isotopiocally-resolved molecular formulas that corre- 35
N. Lane. Analysis of Non-Steady State Stable IsotopeResolve Metabolism ofUDP-GlcNAc and UDP-GalNAc.
spond to the same elemental molecular formula and has
equal numbers oflabeling isotopes are statistically evaluated
in Proceedings of Bioinformatics 2011. 2011. Rome,
using both m/z matching-probabilities from Component 4
Italy: SciTePress, Portugal.
and a log ratio of isotopologue peak intensities statistically
2. Django-The Web framework for perfectionists with
compared to the log ratio of each isotopically-resolved 40
deadlines. Available from: https://www.djangoproject.
molecular formula NAP from Component 1 (log-ratio match
com/.
probability). Each compatible intersecting pair of isotopi3. Carreer, W. J. and H. N. B. Moseley, Correcting for the
cally-resolved molecular formulas represent evidence for
effects of natural abundance in stable isotope resolved
specific elemental molecular formulas (i.e. metabolites) in
metabolomics experiments involving multiple simultanethe mass spectrum. Specific elemental molecular formulas 45
ous isotopic labels and ultra-high resolution mass specare identified by statically evaluating the sum of compatible
trometry Comp Biol Chem, submitted.
intersecting pairs of isotopically-resolved molecular formu4. Moseley, H., Correcting for the effects of natural abunlas that support the same elemental molecular formula. The
dance in stable isotope resolved metabolomics experiresulting analysis identifies a clique of isotopologue peaks
ments involving ultra-high resolution mass spectrometry.
associated with a specific elemental molecular formula (i.e. 50
BMC Bioinformatics, 2010. 11: p. 139.
a metabolite isotopologue-offset clique).
5. Lane, A. N., T. W. Fan, Z. Xie, H. N. Moseley, and R. M.
Component 5b. Algorithms that Identify Super-cliques of
Higashi, Isotopomer analysis oflipid biosynthesis by high
Related Element-resolved Cliques of Isotopologues in a
resolution mass spectrometry and NMR. Analytica
Statistically Robust Manner.
Chimica Acta, 2009. 651(2): p. 201-8.
A pair of detected metabolite isotopologue-offset cliques 55 6. Fan, T. W. M., A. N. Lane, and R. M. Higashi, In vivo and
from Component Sa are statistically compared using the
in vitro metabolomic analysis of anaerobic rice coleopmatrix of log intensity ratios from Component 5b to identify
tiles revealed unexpected pathways. Russian Journal of
super-cliques within a mass spectrum with inter-clique difPlant Physiology, 2003. 50(6): p. 787-793.
7. Fan, T., J. Bird, E. Brodie, and A. Lane, 13C-Isotopomerferences in both elemental and isotope-specific molecular
formulae. These differences reflect additions of known che- 60
based metabolomics of microbial groups isolated from
moselective tags and/or adducts to specific metabolites
two forest soils. Metabolomics, 2009. 5(1): p. 108-122.
represented by the elemental molecular formula of the base
8. Fan, T. W. and A. N. Lane, NMR-based stable isotope
clique.
resolved metabolomics in systems biochemistry. Journal
While not all components of this approach are required to
of Biomolecular NMR, 2011. 49(3-4): p. 267-80.
obtain useful information, employing all five components 65 9. Lane, A. N., T. W. Fan, and R. M. Higashi, Isotopomercan provide for determination of isotopically-resolved
based metabolomic analysis by NMR and mass spectrommolecular formulas of specific isotopologues via the idenetry. Methods Cell Biol, 2008. 84: p. 541-88.
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10. Moseley, H., A. Lane, A. Belshoff, R. Higashi, and T.
Fan, A novel deconvolution method for modeling UDPGlcNAc biosynthetic pathways based on 13C mass isotopologue profiles under non steady-state conditions.
BMC Biology, 2011. 9(1): p. 37.
11. Tomita, E., A. Tanaka, and H. Takahashi, The worst-case
time complexity for generating all maximal cliques and
computational experiments. Theoretical Computer Science, 2006. 363(1): p. 28-42.
12. Cazals, F. and C. Karande, A note on the problem of
reporting maximal cliques. Theoretical Computer Science, 2008. 407(1-3): p. 564-568.
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maximal cliques in sparse graphs in near-optimal time.
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abundance in stable isotope resolved metabolomics
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What is claimed is:
1. A method for mass spectrometry data analysis for
identification of a specific elemental molecular formula
(EMF) for an unknown compound, the method comprising:
calculating a natural abundance probability (NAP) of a
given isotopologue for isotopes of a predetermined
mass and elemental boundary for non-labeling elements of an unknown compound based on chemical
norms for possible structures;
creating caches of non-ionized molecular fragments for a
subset of isotopes identified using the NAP values for
isotopologues above a NAP cutoff which is based on an
expected detection dynamic range for a specific mass
spectrometry instrument;
sorting the caches of molecular fragments into a requisite
cache data structure, to be searched;
characterizing peaks from a raw mass spectrum composed
of multiple scans without spectral nor regional averaging for an unknown compound and separating samplespecific peaks from various spectral artefacts seen in
ultra-high resolution Fourier transform mass spectra;
creating sets of possible isotope-resolved molecular formulae (IMF) by iteratively searching the molecular
fragment caches and combining with additional isotopes and then statistically filtering the results based on
NAP and mass-to-charge (m/z) matching probabilities;
and
identifying an unknown compound and its corresponding
EMF from statistically-significant cliques of isotopologues with compatible IMFs.
2. The method of claim 1, wherein calculating a natural
abundance probability (NAP) of a given isotopologue for
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isotopes of non-labeling elements of an unknown compound
comprises applying the equation:

filtering the set of possible IMF(s) against:
i) the NAP
ii) a statistical measure of how well the molecular formula
matches the m/z ratio (m/z matching probability), and
iii) metabolite bonding pattern rules.
7. The method of claim 1, wherein identifying a metabolite and its corresponding EMF from statistically-significant
cliques of isotopologues with compatible IMFs comprises:
identifying a nonempty intersection between sets of possible EMFs identify from possible IMFs;
statistically evaluating using both the m/z matching probabilities calculated, for each complementary pair of
isotopologues from one of the specific respective EMF
cliques and statistically comparing a log ratio of isotopologue intensities to a log ratio of each of the IMF
NAP,
wherein the isotopologue intensities used in the ratios are
derived from associated
characterized peaks; and
identifying specific EMF cliques identified by statically
evaluating the sum of complementary pair probabilities/likelihoods against a statistical alpha.
8. The method of claim 7, wherein complementary pair of
isotopologues represents a statistically evaluated piece of
evidence supporting the existence of the associate EMF
clique in the mass spectrum.
9. The system of claim 1, wherein identifying a metabolite
and its corresponding EMF from statistically-significant
cliques of isotopologues with compatible IMFs comprises:
identifying a nonempty intersection between sets of possible EMFs identify from possible IMFs;
statistically evaluating using both the m/z matching probabilities calculated, for each complementary pair of
isotopologues from one of the specific respective EMF
cliques and statistically comparing a log ratio of isotopologue intensities to a log ratio of each of the IMF
NAP,
wherein the isotopologue intensities used in the ratios are
derived from associated
characterized peaks; and
identifying specific EMF cliques identified by statically
evaluating the sum of complementary pair probabilities/likelihoods.
10. The method of claim 1, wherein the unknown compound is a metabolite.
11. A system of mass spectrometry data analysis for
identification of a specific elemental molecular formula
(EMF) for an unknown compound, the system comprising:
computer memory adapted to store mass spectrometry
data for an unknown compound; and
a computer processor adapted for performing analytics on
mass spectrometry data from mass spectrometry for the
unknown compound, said processor:
calculating a natural abundance probability (NAP) of a
given isotopologue for isotopes of a predetermined
mass and elemental boundary for non-labeling elements of an unknown compound based on chemical
norms for possible structures;
creating caches of non-ionized molecular fragments for a
subset of isotopes identified using the NAP values for
isotopologues above a NAP cutoff which is based on an
expected detection dynamic range for a specific mass
spectrometry instruction;
sorting the caches of molecular fragments into a requisite
cache data structure, to be searched;
characterizing peaks from a raw mass spectrum composed
of multiple scans without spectral nor regional averag-
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PEJ
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where, in an instance a specific isotope(s) comes from a
labeling source, probability (PE) is omitted from the
calculation.
3. The method of claim 1, wherein creating caches of
non-ionized molecular fragments for a subset of isotopes
identified using the NAP, and sorting the caches of molecular fragments into the requisite cache data structure, comprises:
enumerating molecular fragments for a given set of isotapes within a mass specified mass range,
calculating partial NAP for each molecular fragments,
filtering molecular fragments based on a given NAP
cutoff,
sorting molecular fragments by mass, and
generating a binary or b-tree searchable molecular fragment cache.
4. The method of claim 1, wherein characterizing peaks
from the raw mass spectrum and separating sample-specific
peaks from various spectral artefacts seen in ultra-high
resolution Fourier transform mass spectra comprises:
removing noise peaks from multiple mass spectrometry
scans of the unknown compound,
corresponding peaks across the multiple scans after noise
peaks removed, and
performing normalization of peak heights/areas across
scans.
5. The method of claim 4, wherein identifying a metabolite and its corresponding EMF from statistically-significant
cliques of isotopologues with compatible IMFs comprises:
identifying a nonempty intersection between sets of possible EMFs identify from possible IMFs;
statistically evaluating using both the m/z matching probabilities calculated, for each complementary pair of
isotopologues from one of the specific respective EMF
cliques and statistically comparing a log ratio of isotopologue intensities to a log ratio of each of the IMF
NAP,
wherein the isotopologue intensities used in the ratios are
derived from associated
characterized peaks; and
identifying specific EMF cliques identified by statically
evaluating the sum of complementary pair probabilities/likelihoods.
6. The method of claim 1, wherein creating sets of
possible isotope-resolved molecular formulae (IMF) by
iteratively searching the molecular fragment caches and
combining with additional isotopes and then statistically
filtering the results based on NAP and mass-to-charge (m/z)
matching probabilities comprises:
identifying each isotopologue by a peak with a specific
mass to charge ratio (m/z ratio) position in a ID mass
spectrum;
calculating, for each characterized isotopologue peak,
within a specified accuracy tolerance, using the cache
data structurem, a set of possible, isotopically-resolved
molecular formulas (IMFs) to build the specific IMF(s );
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ing for an unknown compound and separating samplespecific peaks from various spectral artefacts seen in
ultra-high resolution Fourier transform mass spectra;
creating sets of possible isotope-resolved molecular formulae (IMF) by iteratively searching the molecular
fragment caches and combining with additional isotopes and then statistically filtering the results based on
NAP and mass-to-charge (m/z) matching probabilities;
and
identifying an unknown compound and its corresponding
EMF from statistically-significant cliques of isotopo!agues with compatible IMFs.
12. The system of claim 1, wherein calculating a natural
abundance probability (NAP) of a given isotopologue for
isotopes of non-labeling elements of an unknown compound
comprises applying the equation:

38
14. The system of claim 11, wherein characterizing peaks

from the raw mass spectrum and separating sample-specific
peaks from various spectral artefacts seen in ultra-high
resolution Fourier transform mass spectra comprises:
5
removing noise peaks from multiple mass scans of the
unknown compound,
corresponding peaks across the multiple scans after noise
peaks removed, and
performing normalization of peak heights/areas across
10
scans.
15. The system of claim 11, wherein creating sets of
possible isotope-resolved molecular formulae (IMF) by
iteratively searching the molecular fragment caches and
15 combining with additional isotopes and then statistically
filtering the results based on NAP and mass-to-charge (m/z)
matching probabilities comprises:
identifying each isotopologue by a peak with a specific
mass to charge ratio (m/z ratio) position in a ID mass
20
spectrum;
n
NAP=
PEJ
calculating, for each characterized isotopologue peak,
j=l
within a specified accuracy tolerance, using the cache
data structurem, a set of possible isotopically-resolved
molecular formulas (IMFs) to build the specific IMF( s);
where, in an instance a specific isotope(s) comes from a
25
filtering the set of possible IMF(s) against:
labeling source, probability (PE) is omitted from the
calculation.
i) the NAP
13. The system of claim 11, wherein creating caches of
ii) a statistical measure of how well the molecular formula
non-ionized molecular fragments for a subset of isotopes
matches the m/z ratio (m/z matching probability), and
identified using the NAP, and sorting the caches of molecuiii) metabolite bonding pattern rules.
lar fragments into the requisite cache data structure, com- 30
prises
16. The system of claim 11, wherein the caches of
enumerating molecular fragments for a given set of isomolecular fragments are stored in the computer memory
topes within a mass specified mass range,
and/or secondary storage, and said caches in the computer
calculating partial NAP for each molecular fragments,
memory and/or the secondary storage are in an order up to
filtering molecular fragments based on a given NAP 35 multiterabytes in size.
cutoff,
17. The system of claim 11, wherein the unknown comsorting molecular fragments by mass, and
pound is a metabolite.
generating a binary or b-tree searchable molecular fragment cache.
* * * * *
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